| Market Cap | 528.73M | P/E | - | EPS this Y | 27.80% | Ern Qtrly Grth | - |
| Income | -149.24M | Forward P/E | -4.12 | EPS next Y | 51.60% | 50D Avg Chg | 10.00% |
| Sales | 30.26M | PEG | -0.04 | EPS past 5Y | - | 200D Avg Chg | 50.00% |
| Dividend | N/A | Price/Book | 6.41 | EPS next 5Y | 20.00% | 52W High Chg | -6.00% |
| Recommedations | 1.90 | Quick Ratio | 1.90 | Shares Outstanding | 55.08M | 52W Low Chg | 202.00% |
| Insider Own | 0.96% | ROA | -57.75% | Shares Float | 42.89M | Beta | 1.12 |
| Inst Own | 78.71% | ROE | -2,986.55% | Shares Shorted/Prior | 2.90M/2.68M | Price | 10.46 |
| Gross Margin | -221.93% | Profit Margin | - | Avg. Volume | 844,390 | Target Price | 8.50 |
| Oper. Margin | -375.94% | Earnings Date | Nov 5 | Volume | 282,846 | Change | -3.95% |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
| HC Wainwright & Co. | Buy | Aug 14, 24 |
| Ladenburg Thalmann | Neutral | Aug 14, 24 |
| Truist Securities | Buy | Jun 18, 24 |
| HC Wainwright & Co. | Buy | Jun 18, 24 |
| HC Wainwright & Co. | Buy | May 9, 24 |
| HC Wainwright & Co. | Buy | May 7, 24 |
| Truist Securities | Buy | Apr 17, 24 |
| HC Wainwright & Co. | Buy | Apr 16, 24 |
| Baird | Neutral | Apr 16, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Shafer Christina | CHIEF COMMERCIAL OFF.. CHIEF COMMERCIAL OFFICER | Aug 07 | Sell | 9.23 | 2,396 | 22,115 | 40,626 | 08/08/23 |
| Braunstein Scott | CHAIRMAN AND CEO CHAIRMAN AND CEO | Aug 07 | Sell | 9.25 | 6,443 | 59,598 | 160,762 | 08/08/23 |
| Pfanstiel Steven | CFO AND COO CFO AND COO | Aug 07 | Sell | 9.24 | 2,804 | 25,909 | 49,324 | 08/08/23 |
| MANNING MARTHA E | SVP, GEN. COUNSEL &.. SVP, GEN. COUNSEL & CORP. SEC. | Aug 07 | Sell | 9.24 | 2,180 | 20,143 | 33,025 | 08/08/23 |
| Hulihan Joseph | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Aug 07 | Sell | 9.24 | 2,902 | 26,814 | 47,614 | 08/08/23 |